Payment overview · 2025
General Payments
$84.69
5 reported records · 3 companies
Healthcare provider profile · identity verified
Kenneth Steven Braton, DO
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, MO · NPI 1740273465
Verified facts
What the public records show
CMS Open Payments records show Kenneth Steven Braton, DO received $84.69 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 59.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.40 | 59.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.05 | 23.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.24 | 16.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $84.69 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.40 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.77 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 12 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1047 | 301 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 835 | 245 |
| Atorvastatin Calcium | Atorvastatin Calcium | 641 | 179 |
| Losartan Potassium | Losartan Potassium | 489 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 101 |
| Lisinopril | Lisinopril | 358 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 334 | 92 |
| Potassium Chloride | Potassium Chloride | 280 | 91 |
| Metformin Hcl | Metformin Hcl | 270 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 233 | 60 |
| Omeprazole | Omeprazole | 218 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 56 |
| Gabapentin | Gabapentin | 203 | 57 |
| Allopurinol | Allopurinol | 188 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 55 |
| Glimepiride | Glimepiride | 180 | 48 |
| Metformin Hcl Er | Metformin Hcl | 178 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 56 |
| Ezetimibe | Ezetimibe | 152 | 45 |
| Carvedilol | Carvedilol | 146 | 46 |
| Jardiance | Empagliflozin | 139 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 42 |
| Simvastatin | Simvastatin | 111 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 28 |
| Spironolactone | Spironolactone | 85 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 23 |
| Nifedipine Er | Nifedipine | 78 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 22 |
| Furosemide | Furosemide | 74 | 25 |
| Lovastatin | Lovastatin | 74 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 34 |
| Sertraline Hcl | Sertraline Hcl | 69 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 18 |
| Eliquis | Apixaban | 61 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 20 |
| Ozempic | Semaglutide | 57 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 14 |
| Alendronate Sodium | Alendronate Sodium | 52 | 17 |
| Meloxicam | Meloxicam | 51 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 14 |
| Valsartan | Valsartan | 47 | 14 |
| Montelukast Sodium | Montelukast Sodium | 45 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 38 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 13 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 14 |
| Finasteride | Finasteride | 37 | suppressed |
| Klor-Con M10 | Potassium Chloride | 37 | 14 |
| Cephalexin | Cephalexin | 36 | 32 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Klor-Con M20 | Potassium Chloride | 35 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 35 | 12 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 30 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Indapamide | Indapamide | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | 11 |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | 12 |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Cilostazol | Cilostazol | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $84.69 · 5 records | Novo Nordisk Inc | AREXVY, BEXSERO, Ozempic, Rybelsus, SHINGRIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error